Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis

Phase 2 Recruiting 160 enrolled Oruka Therapeutics, Inc.

RandomizedParallel-groupDouble-blindTreatment

Summary

This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.

Timeline

Start: 2025-12-03
Primary completion: 2027-06
Completion: 2028-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ORKA-001	Unknown	37.5 mg	Subcutaneous
Subject	ORKA-001	Unknown	300 mg	Subcutaneous
Subject	ORKA-001	Unknown	600 mg	Subcutaneous

Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis

Summary

Timeline

Drugs

Indications